NEW YORK, NY / ACCESSWIRE / August 21, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novartis AG (“Novartis” or the “Company”) (NYSE:NVS). Investors who purchased Novartis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/nvs.
The investigation concerns whether Novartis and certain of its officers and/or directors have violated federal securities laws.
On August 6, 2019, the U.S. Food and Drug Administration (“FDA”) announced that Novartis had submitted manipulated data in its biologics license application (“BLA”) for its gene therapy drug, Zolgensma. The FDA’s announcement continued to say that the Company “became aware of the issue of the data manipulation that created inaccuracies in their BLA before the FDA approved the product, yet did not inform the FDA until after the product was approved.” Novartis is now under FDA investigation and may be subject to further penalties. Following this news, Novartis stock dropped $2.50 per share, or roughly 3%, to close at $88.22 on August 6, 2019.
If you are aware of any facts relating to this investigation, or purchased Novartis shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/nvs. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com: